⚖
Compare Funds
See how two funds stack up side by side, real returns, risk, cost and portfolio overlap.
VS
Key Metrics Comparison
| Metric | ICICI Prudential Nifty Pharma Index Fund - Growth - Direct Plan | Motilal Oswal NASDAQ Q 50 ETF |
|---|---|---|
| Snapshot | ||
| AMC | — | — |
| Category | Index Funds - Other | ETFs - Other |
| NAV | ₹20.98 (02 Nov 2026) | ₹115.36 (02 Nov 2026) |
| Rating | ★★★★★ | ★★★★★ |
| Benchmark | NIFTY PHARMA - TRI | NASDAQ Q-50-TRI |
| Fund Manager | Nishit Patel | Swapnil P Mayekar |
| Inception | 14 Dec 2022 | 23 Dec 2021 |
| Returns | ||
| 1Y | 22.36% | 31.86% |
| 3Y | 22.30% | 32.09% |
| 5Y | — | — |
| Since Inception | 21.00% | 12.43% |
| Risk | ||
| 13.85 | 18.57 | |
| 0.99 | 0.40 | |
| 1.00 | 1.31 | |
| -0.56 | 24.06 | |
| 2.18 | 2.77 | |
| -9.64% | -16.13% | |
| Costs | ||
| Expense Ratio | 0.51% | 0.56% |
| Exit Load | Nil | — |
| Min SIP | ₹1,000 | — |
| Min Lumpsum | ₹1,000 | ₹500 |
| Lock-in | None | None |
Min SIP is reported per fund, not per plan, every plan of a fund shares the same figure.
Portfolio Overlap
ICICI Prudent…100%
Motilal Oswal…100%
0.0%Only 0.0% of holdings by weight are common between ICICI Prudential Nifty Pharma Index Fund - Growth - Direct Plan and Motilal Oswal NASDAQ Q 50 ETF, based on each fund's top 20 disclosed holdings, not the full portfolio.
Category context: Index / ETF vs Index / ETF. Open the full Screener →